Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610439 · ClinicalTrials.gov registry record
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
A clinical trial of Breast Carcinoma and Neuropathy, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 575
- Enrollment target
- 1
- Study location
NCT02610439 is a study of Breast Carcinoma and Neuropathy that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 575 participants, below the 765-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02610439, a study of Breast Carcinoma and Neuropathy, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 575 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Massachusetts
- Eastern Cooperative Oncology Group - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 575 participants |
| Start Date | 2014-03-25 |
| Est. Completion | 2100-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02610439
The ClinicalTrials.gov registry entry for NCT02610439 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 575 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 765-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (25% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT02610439 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02610439 about?
NCT02610439 is a clinical study titled "Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer". This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropa...
What is the current status of trial NCT02610439?
This trial is currently recruiting. The enrollment target is 575 participants. The study started on 2014-03-25. Estimated completion is 2100-01-01.
What conditions does trial NCT02610439 study?
This clinical trial studies the following conditions: Breast Carcinoma, Neuropathy.
What interventions are being tested in trial NCT02610439?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02610439?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02610439 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.